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in developing countriesMasood Naseripour, MD ⇑AbstractThe patients’ survival for the most common intraocular tumor in children, retinoblastoma, has a wide spectrum among the world
countries. This study was conducted to provide an overview of the retinoblastoma survival disparity worldwide by discussing the
trends of patients’ survival, as well as recent advances in the management of retinoblastoma.
The design of this study was literature review and commentary. Selected articles from PubMed (except one) including both devel-
oping and developed countries regarding the patients’ survival in retinoblastoma were considered and reviewed critically. An anal-
ysis of 47 articles was performed. In conclusion, in spite of an obvious contrast of retinoblastoma survival disparity in the world, the
expanding horizons in developing countries are promising and continuing on all fronts and results are hope-inspiring.
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A historic review of retinoblastoma is a paramount exam-
ple of the advances made in multiple specialty fields to con-
vert a lethal disease with a 5% survival rate in the late 19th
century to a curable disease with the highest rates of survival
between pediatric cancers in 2003.1
This tremendous change was significantly owing to several
techniques and modalities which were developed during the
20th century including advances in the examination of chil-
dren under anesthesia and enucleation,2 external beam radi-
ation,3 brachytherapy,4 photocoagulation5 and cryotherapy.6
In an attempt to avoid enucleation and increase the
globe survival, chemoreduction and focal consolidative ther-
apy became the mainstay of Rb management in the late
1990s.7–10
Although these advances have been associated with
improvement in terms of both patients’ and globe survival,
there are obvious differences between developed and
developing countries. The results of a multicentric study inPeer review under responsibility
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Rb had disease-free survival at 5 and 10 years.11
Broaddus et al. reported an increasing 5 years survival
rate in the US from 92.3% to 96.5% over a period of
30 years (1975–2004).12 In contrast, published data from
less-developed countries13 revealed a much lower mean
survival rate ranging from 40% (23–70%) in lower-income
countries to 79% (54–93%) in upper-middle-income
countries.
The objective of this study is to show that in spite of dif-
ferent landscapes between countries, we do see the
expanding horizon in developing or less-developed coun-
tries in terms of both patients’ and globe survival. In order
to compare the outcome of patients with Rb, the World
Bank’s classification of countries has been used (http://
web.worldbank.org). The groups are classified to: low-in-
come (LICs), $1005 or less; lower-middle-income (L-MICs),
$1006–$3975; upper-middle-income (U-MICs), $3976–
$12,275; and high-income countries (HICs), $12,276 or
more.j Production and hosting by ElsevierAccess this article online: www.saudiophthaljournal.comwww.sciencedirect.com
5 February 2012; available online 18 February 2012.
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Problems and priorities in developed countries
In developed nations where the current management of
Rb has resulted in an improved survival to a rate of
astounding 99% with more than 90% retaining normal vi-
sual acuity in at least one eye,1 the intraocular disease
has been successfully treated. These results have been
associated with reduction in the enucleation rate particu-
larly for bilateral disease, and generally, with better visual
outcomes.14 Usually a treatment plan is formulated in a
multidisciplinary approach in collaboration with an ocular
oncologist, a pediatric oncologist, a pediatric radiation
oncologist, a pathologist and a geneticist.15 The rate of
enucleation has been decreased by the use of a combina-
tion of chemoreduction and the focal therapy16 and appli-
cation of new modalities such as chemosurgery17 for
patients with advanced intraocular involvement. Since
93% of the RB1 mutations can be identified in reference
laboratories18 the future trend is toward finding more
about the phenotype and the genotype correlation and
customized target therapy in these countries.19,20
The mean age at diagnosis in North America and Europe,
is 12 and 9 months with a median follow-up 3 and 5 years,
respectively.21 Although the extraocular extension (EOE)
and metastatic disease are the main causes of mortality in
children with retinoblastoma, these are unusual clinical pre-
sentations in developed countries.22,23 The reported 5 years
survival rates of 88–93%,24 from these countries is owing to
the presence of multidisciplinary approach and state-of-the
art centers in management of these patients as well as earlier
diagnosis of the disease. As a result, the leading cause of
mortality is not the primary Rb itself or EOE, but rather sec-
ondary non-ocular tumors that can develop in bilateral cases
with a germinal mutation.25 In such an environment, one can
find some ambitious goals in the Canadian network: no child
will lose both eyes to retinoblastoma; no child will die of
retinoblastoma; and each child and family will experience
optimal care, including access to timely diagnosis and
appropriate care as close to home as possible, with mini-
mal disruption of family life.21Problems and priorities in upper-middle-income
countries
In this group the ultimate goal is to diagnose the disease
before extraocular extension or distance metastasis in order
to save the life of the patient and treat the eye with less-
aggressive treatments to avoid enucleation as much as possi-
ble. During the last decade, much coordinated effort has
been performed at multiple levels, to improve the outcomes
in children with retinoblastoma.
The development of a retinoblastoma program, multidis-
ciplinary approach and support by hospital administrations
in collaboration with governmental and non-governmental
organizations have been reported from different countries.
Authors from Taiwan,26 indicated that the implementation
of the national health insurance program was associated
with earlier diagnosis and better survival rates in patients
with Rb. The published results from Iran,27,28 revealed that
the 5 years survival rate of retinoblastoma has increasedfrom 69% to 83% in the period of 1991–2001 to 2001–
2007. Recent unpublished data show that this rate has im-
proved to 88%. Late clinical presentation with proptosis
was decreased significantly from 7.6% to 1.1% for those
periods of time, respectively. The reports from Turkey,29,30
have indicated that the median age of children with Rb has
decreased from 26 to 18 months for the period of 1964–
1994 compared to 1996–2003. The same declining trend
is evident for the frequency of orbital mass as a presenting
sign of Rb in those studies which in turn have led to im-
proved patients’ survival. Authors from Saudi Arabia,31
have also reported that decrease in the number of patients
presenting with extraocular disease is attributed to an in-
crease in the awareness of retinoblastoma. Encouraging re-
sults have also been reported from Brazil, Argentina and
Mexico32–34 in terms of decreased mortality rate, treating
patients with extraocular disease and the development of
centers of excellence for a conservative management of
Rb. On the contrary, in some affluent countries such as
Malaysia,35 and South Africa36 these results are distressing.
Menon et al.35 reported 55% of extraocular disease inci-
dence in Malaysian children with Rb due to late presenta-
tion and high rates of abandonment.Problems and priorities in lower-middle-income and
lower-income countries
Although the majority of retinoblastoma cases live in this
group, the complexity of management and high incidence
of extraocular extension have resulted in lower cure rate
and subsequent decreased life expectancy. Two well-known
risk factors, the delay in the diagnosis of Rb37 and treat-
ment abandonment/refusal of enucleation also compromise
an advancing survival rate. Although, life-saving therapy via
enucleation is accessible, the stigma attached to the eye
removal, usually leads to high rates of therapy abandon-
ment and a subsequent extraocular extension of the tumor.
One can also see a wide spectrum of social context and
large disparities in socioeconomics and cultural background
as well as differences in health care system among these
countries which can justify the wide range of survival dis-
parity between them. To improve the clinical situation,
the recognition of the main problem plays a critical role
in the management of Rb in this group. For example, ab-
sence of the Rb program was associated with poor survival
in El Salvador, Guatemala and Honduras in Central Amer-
ica.38 The introduction of twinning initiatives ended up in
patients abandoning/refusing treatment drop-off in Guate-
mala from 21% to 11% and in Honduras from 35% to
19% of patients. On the other hand, education of primary
care providers in different ways was associated with earlier
diagnosis in these countries. Consequently, development of
the Rb program and earlier diagnosis of patients led to a
dramatic decrease of extraocular disease from 73% to
35%.38 Although, the limited resources in less-developed
countries are a big challenge to develop a state-of-the
art center similar to the developed countries this problem
has been resolved with the implementation of a center with
modern treatments and technology by a not-for-profit
organization such as The Sankara Nethralaya Foundation
in India.39 Even though the proptotic eye presentation in
Sitorus et al. report40 from Indonesia, is high (49.1%) for
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port41 for period of 1980–1988 from that country, the
trend for this advanced presenting sign is declining
(91.3% vs. 49.1%). Similar results have indicated a decreas-
ing trend in extraocular presentation from 90% to 34% (9/
26) in children with retinoblastoma from Ibadan,
Nigeria.42,43
Table 1 shows the schematic overview of the situation
worldwide according to country classification, as determined
by The World Bank.Discussion
Based on the context, different scenarios may apply to
each group of countries. Similar problems may require differ-
ent approaches depending on the context in which they oc-
cur. In spite of the huge disparities between developed and
less-developed countries, the trend in less-developed coun-
tries is promising. This is in contrast to the study by Gallie
and coworkers21 who believe that the majority of the 8000
children afflicted worldwide have not benefited from these
trends. In case of the lack of Rb program, as it has been
emphasized by international authors in the ‘‘One World,
One Vision’’ symposium,45 a careful evaluation of the context
and a needs assessment (including team and infrastructure)
must be performed, and efforts must be unified for the devel-
opment of a successful Rb program. Such a survey can help the
public and hospital administration to select the best fit pro-
gram to develop. One of the best approaches to set-up a pro-
gram in lack of the infrastructure and multidisciplinary team is
the ‘‘twinning program’’ using communication technology.
The construction of a center of excellence in Jordan,46 is a re-
sult of such a successful program which in turn led to improve-
ment of patients care immediately. Although the effect of aTable 1. Basic differences in retinoblastoma management worldwide.
Factor(s) High-income countries Up
co
National cancer registry for
Rb
Usually present So
Research program Well structured randomized clinical trials
(RCT) and epidemiological studies
Re
oth
Benefit of molecular
diagnosis
Always present So
Health care infrastructure Well established Le
Multidisciplinary approach
for management of Rb
Always present Is
pr
Availability of essential
medication
Always available Us
Lag time to diagnosis Less than 3 months Be
Age at diagnosis Less than 18 Be
Financial support Mainly from government and
foundations
Fro
go
Oncology center State-of-the art centers (O
on
Main presenting sign Leukocoria, strabismus Le
pr
Treatment abandonment Less than 1% Ab
Public and professional
awareness
In good condition In
Goal of treatment Eye and vision preservation Lif
pr
a Including lower-middle-income countries.
b The descriptions are relative.socioeconomic condition on treatment refusal/abandonment
should not be ignored in less-developed countries,13 consis-
tent with Sitorus and coworkers,40 it seems that financial con-
straints have a bigger effect on parents whose child already
has a proptotic eye and obvious extraocular extension. Mean-
while in cases with only advanced intraocular disease the par-
ents tend to refuse or delay the recommended enucleation or
chemotherapy, mostly because of personal, psychological,
cultural/religious and less frequent financial reasons. Probably,
one of the most important reasons to refuse the recom-
mended treatment (enucleation) is a stigma/defect attached
to the eye removal or blindness. This differs from reported
studies from African countries like Senegal,47 and Nigeria42
were treatment abandonment has been mostly related to
financial constraints and lack of drug availability.
In a recent systematic review of publication, Canturk
et al.13 reported the estimated survival of retinoblastoma in
less-developed countries (LDCs). They classified the countries
to low-income countries (LICs), lower-middle-income coun-
tries (L-MICs) and upper-middle-income countries (U-MICs).
The estimated survival rates for LICs, L-MICs and U-MICs
were 40%, 77% and 79%, respectively. They also found the
occurrence of metastasis in 32%, 12% and 9.5% accordingly.
Even though this study enjoys the big advantage of contain-
ing important information regarding the survival rate from
LDCs that have never been pointed out in any other article,
it has some flaws as have been indicated by the authors
too. First, about 20% of the papers included patients treated
before 1990 (before chemoreduction era), secondly, socio-
economic and health-related indicators were obtained from
the WHO report for 2000, (which may be changed signifi-
cantly now) except for the maternal mortality rate and fertility
rate, thirdly, significant publications might have been missed
and fourth, various methods and follow-up time used in these
reports could compromise the estimated survival. Movingper-middle-income
untries
Low-incomea countriesb
metimes present Usually absent
search collaboration with
er countries
Mainly conducted and supported by
international organization
metimes present Usually absent
ss established Lack of system
developing or sometimes
esent
Usually absent
ually available Hardly available
tween 3 and 6 months More than 6 months
tween 18 and 30 More than 24
m non-governmental and
vernmental organizations
Usually from international organizations
and sometimes from government
cular)Oncology service and
cology department
Regional oncology centers of reference
ukocoria, strabismus and
optosis
Leukocoria, proptosis and extraocular
extension
out 5% 30–40%44
fair condition Scarcity of awareness
e saving and eye
eservation
Life saving
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about one thousand patients (which is now classified as a U-
MIC country) can change the results dramatically. So as a re-
sult, the survival of patients with retinoblastoma might be
better at least in some aspects. In many countries financial
problems for parents have been decreased by some non-
profit organization or specific governmental support, but it
seems that many other low-income countries need to be sup-
ported by other high-income countries or some international
organizations such as WHO (World Health Organization) or
The International Agency for Prevention of Blindness to pro-
vide the essential medicine and modalities for the manage-
ment of patients with Rb.
In conclusion, in spite of the obvious contrast of retino-
blastoma survival disparity in the world, the expanding hori-
zons in developing countries is promising and continuing
on all fronts and results are hope-inspiring.References
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